Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Volume 12
Erscheinungsjahr 2020
ISBN: 978-0-12-821310-0
Verlag: Elsevier Science

Buch, Englisch, 308 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 810 g

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance.

Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges.

Autoren/Hrsg.

Freywald, Andrew

Vizeacoumar, Franco

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Chemotherapie

Inhaltsverzeichnis

1. Introductory Chapter2. Tumor Metabolic Reprogramming in Therapeutic Resistance3. Development of novel antiandrogens to overcome castrate resistant prostate cancer4. Microenvironmental regulation of cancer response to therapy and therapy resistance5. Revisiting immunogenic cell death to overcome treatment resistance in cancer immunotherapy6. Preventing Phenotypic Plasticity in Cancer to Mitigate Therapy Resistance7. Overcoming drug resistance in cancer with targeted radionuclide therapy8. The PI3K pathway and chemotherapy resistance9. Targeting leukemia stem cells in T-cell acute lymphoblastic leukemia10. Escape from apoptosis: Anastasis as a potential mechanism of cancer drug resistance11. From genetic data and structures to drug development: new approaches to targeting Eph receptors12. Overcoming Therapeutic Resistance in Glioblastoma: a major clinical challenge

Über Autor(innen)

Vizeacoumar, Franco
Dr. Franco J. Vizeacoumar, obtained his PhD in cell biology at the University of Alberta, Canada, and did his post-doctorate at the University of Toronto, Canada. His lab is working on developing genotype-directed cancer therapies for solid tumors by applying basic biological concepts called synthetic lethality and synthetic dosage lethality. The long term goal of his research group is to build a unified human genetic network that will capture genetic dependencies of cancer cells and define key therapeutic targets. The work in the Vizeacoumar lab has been supported by multiple granting agencies, such as CIHR, SCA, CRS, SHRF, CFI, TFRI, PCC, and also by the Be Like Bruce organization and the College of Medicine at the University of Saskatchewan.

Freywald, Andrew
Dr. Andrew Freywald, obtained his PhD in molecular and cell biology at the Weizmann Institute of Science, Israel, and completed his post-doctorate training in molecular immunology and cancer research at the Hospital for Sick Children, Toronto, Canada. His current research interests include cancer cell biology and tumor biology. He also serves as a scientific advisor for the biotech industry. The work of his research team at the College of Medicine, University of Saskatchewan focuses on investigating and targeting molecular mechanisms that determine tumor aggressiveness, and treatment resistance. His research program has been supported by several granting agencies, including CIHR, CCSRI, SHRF CRS, CFI, SCA, PCC, CBCF and TFRI, and also by the Be Like Bruce organization and the College of Medicine, University of Saskatchewan.